Please assess the completion status of the following clinical trial:

Trial Title: Imaging Study to Investigate Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence (SPOTLIGHT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient is male and aged \>18 years old.~2. History of localized adenocarcinoma of the prostate with prior curative intent treatment.~3. An elevated PSA, clinically suspicious for biochemically recurrent disease:~   * Following Radical Prostatectomy: PSA \>0.2 ng/mL~  * Following Radiotherapy: nadir +2 ng/mL.~4. Potentially eligible for salvage therapy with curative intent.~Exclusion Criteria:~1. Patients who are planned to have an x-ray contrast agent or other PET radiotracer \<24 hours prior to the PET scan.~2. Patients currently receiving Androgen Deprivation Therapy (ADT).

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients (Type: EXPERIMENTAL): Single intravenous administration of rhPSMA-7.3 (18F) for PET Scan

Based on this trial design, predict the completion outcome and termination type (if applicable).